Physiomics Share Discussion Threads

[minja19] 15/2/2018 16:46

PWhite73,
I had to access the server, to retrieve your “original” post from this morning @ 11.57 GMT
………………………………............................

PWhite73 15 Feb '18 - 11:57 - 1679

"Do you see red ticks everywhere "?
You may be suffering from a little known disease called Crimsonitis.
We at Healthcare Advance have over 15 years experience of treating patients with this rare but debilitating disease. Why not give us a no obligation call on 0800 778 6745 or email us at HA/Crimson.org.uk.


(Which you later edited to
PWhite73 15 Feb '18 - 11:57 - 1679
I've said before I don't red tick anybody. Just what is the point)
……………………………….............................

What this clearly demonstrates, (apart from you having the complete set, of root mental afflictions) is that your post last week on 13 Feb is 100% correct

PWhite73 - 13 Feb 2018 - 09:02:09 - 1631 of 1678

“Just one another thing Minja19 you are not in my league and I think you are slowly becoming aware of it”
.................
100% correct PWhite,
you are undoubtedly in a very special league, completely on your own.

FRIENDLY WARNING all your posts are on the server,
So before you post in future, I advise you to double check your content, so that at a later stage you don’t feel the need to completely delete your posts, or heavily edit them…… enjoy the rest of your miserable day.

[myamay16] 15/2/2018 14:37

Maybe Physiomics will be called upon by a Pharma to assist.

Cancer Research UK has announced that £45 million will be invested into its network of clinical trials units across the UK, one of the charity£s largest investments in clinical research to date.

Clinical trials are the only way to find out if a new treatment is safe to use, and if it£s better than existing treatments. Hence, this investment is essential for better future options for patients.

hxxps://www.braintumourresearch.org/media/news/news-item/2018/02/15/brain-tumour-research-welcomes-commitment-to-the-funding-of-clinical-trials-for-cancer-treatment

[pwhite73] 15/2/2018 11:57

I've said before I don't red tick anybody. Just what is the point.

[the stigologist] 15/2/2018 09:10

Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15"


ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892

Writing as a Founder of Physiomics

I am a shareholder but do not represent the company in any capacity.

WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million

*It is first to market

*Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel )

*The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time.

* The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer

*Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced

*PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials
( drug failure )

*The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials.

* Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been )

*In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval

*In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points

* PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications.

* Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century

* PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially.

To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued

[the stigologist] 15/2/2018 09:09

PWhite73 - 11 Jul 2017 - 07:57:10 - 2779 of 4877

Looking at the sales of late I do believe this is the end of the listing now.


PWhite73 - 04 May 2017 - 23:44:56 - 2767 of 4877

1.0p on the bid. All hope now rests with law enforcement agencies.

[pwhite73] 15/2/2018 08:59

That's good. Your constant spamming of the thread with the same articles helps to educate investors that there is something not quite right here. The more that get out before the MM trash the stock back down to 2p the better.

[the stigologist] 15/2/2018 08:56

Ex Founder of Physiomics (PYC) Peter Hoskins who writes on ADVFN as "ant15"


ant15 - 30 Nov 2017 - 15:07:26 - 3710 of 4892

Writing as a Founder of Physiomics

I am a shareholder but do not represent the company in any capacity.

WHY THIS SHARE IS WORTH A £1.00 giving it a market cap of still less than £60.million

*It is first to market

*Scarcity of trained personnel in what is still an emergent technology ( there are currently over a 1000 vacancies to be filled in this sector and few trained personnel )

*The development time needed to populate models and most importantly the availability of patient data that needs to be accessed apart from what is available in the literature is protracted PYC has been through this curve perfecting its models over time.

* The Biometric Grant serves to demonstrate not only the faith in the company but also underpins the access PYC is being given to Patient data In this case in the field of Oesophgeal Cancer

*Collaborations with major pharmas have been constrained whilst the models are perfected and due to the secretive nature of all pharmas who generally speaking do not want to share data. The latest contract has dramatically increased the visibility of what PYC do and do best and will encourage a raft of Biotech analysts to write it up as more contracts are announced

*PYC's Cardiac Toxicity Model is 50% plus better than any other available on the market Why is this important? it is the major cause of attrition in clinical trials
( drug failure )

*The cost savings PYC is able to realise for major Pharma is key and further to small Biotechnology companies whose funding is limited as they try to move molecules into clinical trials.

* Big Pharmas feed their development pipelines by acquiring or licensing in small bio's however these sales have moved progressively from Targets 20 years ago to IND candidates and onto Phase 1/2 putting the burden of proof onto the small Bio Techs who need to conserve and raise cash ( not easy and never has been )

*In 2010 Scientific American stated the cost of Development of a drug from start to finish FDA approval was $1.4 billion...In 2016 Association of British Pharmaceutical Industry Has upped this to £1.5 billion ( sterling) a really significant increase. NOTING that only 1 in 5000 drugs get final approval and this is not factored into the costs as above as representing only a successful transition of 1 drug to approval

*In America alone $12-%14 billion per year is spent on Animal Testing Robert Solari a senior research fellow at Imperial College states "The predictive power of biology in reseach is relatively poor in research labs" and notes that the efficacy of animal testing are not particulary predictive of Human Efficacy PYC is "in Silico" ( in computer) its accuracy is one of its major plus points

* PYC is striving to personalised medicine The HOLY GRAIL with tremendous Social and Financial Implications.

* Sooner rather than later The FDA in America will have to recognise that rational drugs designed in computers can be tested in them too saving countless millions of development costs and most importantly time taken to approval ie move from the 20 to the 21st century

* PYC has taken time to develop its excellent technology I believe I have cited the reasons for its true value. It has been challenged in recent times but has now become of age an is exceptionally well positioned in a market sector that is set to expand exponentially.

To recap A leading British Technology currently way undervalued and one that is not a speculative BUY It has proven technology in a burgeoning sector and might well become the focus of an acquisition target as it is still so undervalued

[the stigologist] 15/2/2018 08:54

PWhite73 - 11 Jul 2017 - 07:57:10 - 2779 of 4877

Looking at the sales of late I do believe this is the end of the listing now.


PWhite73 - 04 May 2017 - 23:44:56 - 2767 of 4877

1.0p on the bid. All hope now rests with law enforcement agencies.

[pwhite73] 15/2/2018 08:46

One final word. The selling of late does not justify the fall. What's happening is that the MM are pulling down the stock irrespective so everybody is losing money. That's where the money from placings come from, its how the market operates.

When the MM can't pull the stock down any further that's when the nomads advise the company to do a placing. So the stock that you bought at say 7p is replaced by stock at 2p. Everybody makes money except us.

Gone

[cool hand kev] 15/2/2018 08:46

PWhite73 :

Perhaps you could set up an "Aim Gamblers Anonymous" Self help group for us addicts who have spent years losing a fortune on the stock market.
Would it be held in the Church Hall?

[pwhite73] 15/2/2018 08:38

subiaco

I care about PIs like us losing money. In many cases the companies themselves are not blame PYC is an example. Its the scamming, nomads, market makers, and wealthy traders like JC. Two levels of trickery are required for them to be successful.

1. Firstly to trick mug PIs

2. Secondly and even more important is to get mug PIs to trick even thicker mug PIs.

Occasionally its between 1 and 2 that I step in. And I say occasionally because you will see from my posting history I don't post all over the place despite what those who fall into the secondary category say.

Speak Later

[subiaco] 15/2/2018 08:18

PWhite, why do you care so much?

[pwhite73] 15/2/2018 08:17

On 27/11/2017 the shares could be bought for 1p. There is still a 700% rise reflected in the stock value equivalent to £4 million market value. Nothing has materially changed here. If you sit still the market makers will strip all this money out.

Multi-millionaire Jason Cropper saw no reason to hold this stock any longer than it took to fleece Joe Mug PI of a couple of gran. I'm not sure why any of you are still holding.

[minja19] 14/2/2018 15:37

judge, a couple of good posts. well said.

edit to add .. this post was red ticked within 25 seconds, lol

[the stigologist] 14/2/2018 15:23

Physiomics have delivered in spades on their promise of getting substantial Big Pharma contracts

They've delivered on getting NEW Major Pharmas to engage

There are another 50 odd clients now who will no doubt be re-assessing and wanting to get on board

50 x £30k = £1.5m
50 x £70k = £3.5m
50 x £500k = £25m

The potential on that Direct B2B side is huge
Then add the Indirect B2B side by exploiting alternative routes to market with a larger service provider... B2B sown up and on the way to a 50-100p share price

Now add the Personalised Medicine arm which is looking such a great opportunity and where PYC say they have access to SUBSTANTIAL NON-DILUTIVE funding. This area could see mulitples of 50/100p frankly if they pull it off and why shouldn't they when they are validated and partnered by UK Government, Cancer Research UK and Prof Middleton of Oxford University !

[the stigologist] 14/2/2018 15:00

Introduction

The Company has consolidated its position during the first year of Dr Jim Millen's tenure as CEO and invested in talent development, business development, extending the relationship with a major client and the diversification into the personalised medicine space.

The Company has had significant success in maintaining and extending its relationship with a major pharma client and established or re-established contact with more than fifty potential clients (in some cases past clients) over the course of the year. The Directors believe that leveraging the Company's capabilities and technology into the related discipline of personalised medicine will, if successful, create significant shareholder value.

The key areas of focus for the Company are outlined in this statement and explored further in the Strategic Report.

Modelling and simulation utilising Virtual Tumour Clinical

The Company's main commercial revenue driver continues to be the Virtual Tumour ("VT") predictive software and its development to allow predictions in the clinical space. This will remain the focus for commercial pharmaceutical and biotech clients although other services continue to be sold opportunistically. In particular, the Company has invested significant effort to deepen its relationship with a major client and, as previously announced, is in an active term sheet discussion on a deal that would, if successful, deliver substantial revenues over a multi-year period.

Exploration of collaborations with other service providers

Although the Directors believe the Company has a unique offering, it clearly has fewer opportunities to develop new business than broader based companies (e.g. contract research organisations) which offer services across a spectrum of R&D activity. On the other hand, we do not believe these companies have our capability in the oncology predictive modelling space. As a result, the Company has explored the potential for collaboration with other such service providers and will continue to do so in its next financial year.

Personalised medicine

The personalised medicine initiative is aimed at improving the successful treatment of cancer patients, turning dosing and management from being an art form to being a science. Following the Company's early success in winning a competitive Innovate UK grant in this space and encouraging results from its feasibility project (due to complete in January 2018), the Company has identified other non-dilutive funding opportunities in this space and intends to pursue these where appropriate. There appears to be a significant level of investor and government interest in developing technologies in this area.

[judge grinder] 14/2/2018 11:40

PWhite, I am more than 100% comfortable with my assessment of the situation. Considering your overarching presence and somewhat bizarre posts, I have you pegged as a troll, for reasons best known to yourself and/or your pluscoin sponsors. As such I will not be engaging with you further, but I wish you good fortune with your investments.

[the stigologist] 14/2/2018 09:55

Making slightly higher lows on each 'retracement', and we know how it spikes on news so this all looks very good technically.

Of course the fundamentals should be seeing us at 50-100p right now so the chart is still in catch-up mode

1p to 32p to 7p move repeat in percentage terms from a 7p base would be spike peak of 224p and new higher 'base' of 49p+

[pwhite73] 14/2/2018 09:28

judge grinder The pluscoin is nothing whatsoever to do with me. I never signed up to it or have I ever bought any coins. I think it happens automatically or others can pluscoin your posts. For the record I complained to ADVFN about it myself when people were using pluscoins to hide others posts. The practice has now stopped.

[the stigologist] 14/2/2018 09:26

I notice a lot of small brain limp wristed so called shareholders sold because of deramping

I think we ought to thank £500 Dave for that. Will make the shareholder base stronger for the upcoming rise.